CLDX vs. ALKS, LGND, BCRX, FOLD, INVA, DVAX, MNKD, OPK, NVAX, and GERN
Should you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), and Geron (GERN). These companies are all part of the "biotechnology" industry.
Celldex Therapeutics vs. Its Competitors
Alkermes (NASDAQ:ALKS) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.
Alkermes currently has a consensus price target of $40.00, indicating a potential upside of 36.85%. Celldex Therapeutics has a consensus price target of $50.11, indicating a potential upside of 138.85%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Alkermes.
95.2% of Alkermes shares are owned by institutional investors. 4.4% of Alkermes shares are owned by insiders. Comparatively, 4.4% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Alkermes has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.
Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Alkermes has a net margin of 23.30% compared to Celldex Therapeutics' net margin of -2,366.07%. Alkermes' return on equity of 27.52% beat Celldex Therapeutics' return on equity.
In the previous week, Alkermes had 9 more articles in the media than Celldex Therapeutics. MarketBeat recorded 10 mentions for Alkermes and 1 mentions for Celldex Therapeutics. Alkermes' average media sentiment score of 1.19 beat Celldex Therapeutics' score of 1.16 indicating that Alkermes is being referred to more favorably in the media.
Summary
Alkermes beats Celldex Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Celldex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celldex Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CLDX) was last updated on 7/8/2025 by MarketBeat.com Staff
